KLTO
Klotho Neurosciences, Inc. Common StockKLTO
KLTO
About: Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
Employees: 3
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
11% more funds holding
Funds holding: 9 [Q4 2024] → 10 (+1) [Q1 2025]
1.61% less ownership
Funds ownership: 4.73% [Q4 2024] → 3.12% (-1.61%) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
61% less capital invested
Capital invested by funds: $487K [Q4 2024] → $192K (-$295K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for KLTO.
Financial journalist opinion
Based on 8 articles about KLTO published over the past 30 days
Neutral
PRNewsWire
4 days ago
UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
Company to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK , July 25, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity. In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform.
Neutral
PRNewsWire
6 days ago
Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK , July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced today that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity. In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform.
Neutral
PRNewsWire
1 week ago
Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
NEW YORK , July 22, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), announced that it is partnering with AAVnerGene Inc. (AAVnerGene), a Rockville, MD-based innovation-driven biotech renowned for its transformative technologies in AAV manufacturing and tissue-targeted delivery. Dr. Joseph Sinkule, the CEO of KLTO stated "we announced previously that we have been looking for a more efficient, 'next-generation' method to manufacture several of our patented gene therapy candidates, and the two platform technologies offered by AAVnerGene will catapult our product candidates into the clinic at a faster pace, at a lower cost, a higher efficacy and purity compared to the current state-of-the-art AAV manufacturing processes.
Neutral
PRNewsWire
2 weeks ago
Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules
Klotho Neurosciences Maintains Listing on the NASDAQ NEW YORK , July 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that it had received a notification letter from The NASDAQ Stock Market LLC confirming that the Company has regained compliance with the minimum $1.00 bid price under NASDAQ Listing Rule 5550(a)(2), and the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1). The Company is now in full compliance with all NASDAQ continued listing requirements and will remain listed and traded on the NASDAQ Stock Market.
Positive
Proactive Investors
2 weeks ago
Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug Designation
Klotho Neurosciences (NASDAQ:KLTOW) announced that its novel therapy KLTO-202, also known as s-KL-AAV.myo, for the treatment of Amyotrophic Lateral Sclerosis (ALS) has received Orphan Drug Designation from the US Food and Drug Administration (FDA), The news sent Klotho's shares higher in early trade on Thursday, up 5.8% at about $1.45. ALS is a rare, progressive neurodegenerative disease commonly known as Lou Gehrig's disease.
Neutral
PRNewsWire
2 weeks ago
Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
NEW YORK , July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's novel secreted-Klotho (s-KL) promoter, gene and delivery system (KLTO-202, or s-KL-AAV.myo) for the treatment of ALS. The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. The Orphan Drug Designation provides certain incentives, such as tax credits, toward the cost of human clinical trials and a waiver for the payment of the GDUFA User Fee for market applications.
Positive
Benzinga
4 weeks ago
This Penny Stock Exploded 500% In June: What You Need To Know
Shares of the anti-aging biogenetics company Klotho Neurosciences, Inc. KLTO are on retail investors' radars after the stock exploded by more than 500% in June. Here's a look at recent catalysts that sent the stock soaring.
Neutral
PRNewsWire
1 month ago
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK , June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered cell therapies.
Neutral
PRNewsWire
1 month ago
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population
NEW YORK , June 24, 2025 /PRNewswire/ -- Klotho Neuroscience, Inc. (NASDAQ: KLTO), a US-based biogenetics company developing cell and gene- based treatments to address neurological conditions, including ALS, Alzheimer's Disease (AD) and Parkinson's Disease (PD), has announced that it is partnering with Drs. Makoto Suzuki, Craig and Bradley Willcox, Richard Allsopp, and Michio Shimabukuro of the Okinawa Research Center for Longevity Science (ORCLS), as part of its research program on Okinawa, Japan, where a comparatively high number people live extremely long and healthy lives, many reaching 100 years and more.
Neutral
PRNewsWire
1 month ago
KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS
Key highlights of the announcement include: Elimination of Future Dilution: The Company will no longer be required to issue new common stock to SkyBell, which would have resulted in SkyBell owning 90% of the Company—substantially diluting existing shareholders. No Liability: Neither Klotho nor SkyBell will incur any liability as a result of the termination.
Charts implemented using Lightweight Charts™